Open Access

Isolation and identification of tumor‑initiating cell properties in human gallbladder cancer cell lines using the marker cluster of differentiation 133

  • Authors:
    • Jiwei Yu
    • Zhaohui Tang
    • Wei Gong
    • Mingdi Zhang
    • Zhiwei Quan
  • View Affiliations

  • Published online on: October 10, 2017     https://doi.org/10.3892/ol.2017.7159
  • Pages: 7111-7120
  • Copyright: © Yu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study aimed to isolate and identify the properties of the cluster of differentiation (CD)133+ subset in human gallbladder cancer cells. The CD133+ and CD133‑ subpopulations of the GBC‑SD cell line were separated using immunomagnetic separation, and the biological features of the two subpopulations were analyzed in vitro and in vivo. In particular, the present study aimed to determine whether the two subpopulations were resistant to anti‑tumor reagents and to identify the underlying molecular mechanisms involved. Following cell sorting of GBC‑SD cells using immunomagnetic beads, 90.2±2% of cells were identified as CD133+. Immunofluorescence confirmed that CD133 was expressed at higher levels in the Cd133+ group compared with the CD133‑ group. The proliferation of the CD133+ group was significantly increased compared with the CD133‑ group in vitro and in vivo. Following treatment with fluorouracil or gemcitabine, cells in the CD133+ group exhibited a decreased sensitivity to these drugs. The number of transmembrane cells was significantly increased in the CD133+ group compared with the CD133‑ group. In addition, the expression levels of ATP binding cassette subfamily G member 2, CD44, C‑X‑C motif chemokine receptor 4 (CXCR4), phosphorylated-protein kinase B (Akt) and CD133 in the CD133+ group were significantly increased, compared with those in the CD133‑ group. In CD133+ GBC‑SD cells, stromal cell‑derived factor 1α (SDF‑1α) or treatment with AMD3100, an inhibitor of CXCR4, promotes or suppresses the SDF‑1α/CXCR4 axis, respectively, resulting in increased or decreased CD133 expression through the Akt signaling pathway. Inhibition of the Akt signaling pathway resulted in decreased CD133 expression in GBC‑SD cells. Immunomagnetic beads were successfully used for isolation of the CD133+ subset from GBC‑SD cells. Furthermore, the CD133+ subset revealed an increased potential for tumor formation, cell proliferation, invasion and resistance to chemotherapeutic agents with expression of stem cell‑associated genes. Therefore, in GBC‑SD cells, the CXCR4/Akt/CD133 signaling pathways may be activated.
View Figures
View References

Related Articles

Journal Cover

December-2017
Volume 14 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yu J, Tang Z, Gong W, Zhang M and Quan Z: Isolation and identification of tumor‑initiating cell properties in human gallbladder cancer cell lines using the marker cluster of differentiation 133. Oncol Lett 14: 7111-7120, 2017.
APA
Yu, J., Tang, Z., Gong, W., Zhang, M., & Quan, Z. (2017). Isolation and identification of tumor‑initiating cell properties in human gallbladder cancer cell lines using the marker cluster of differentiation 133. Oncology Letters, 14, 7111-7120. https://doi.org/10.3892/ol.2017.7159
MLA
Yu, J., Tang, Z., Gong, W., Zhang, M., Quan, Z."Isolation and identification of tumor‑initiating cell properties in human gallbladder cancer cell lines using the marker cluster of differentiation 133". Oncology Letters 14.6 (2017): 7111-7120.
Chicago
Yu, J., Tang, Z., Gong, W., Zhang, M., Quan, Z."Isolation and identification of tumor‑initiating cell properties in human gallbladder cancer cell lines using the marker cluster of differentiation 133". Oncology Letters 14, no. 6 (2017): 7111-7120. https://doi.org/10.3892/ol.2017.7159